Notice: Trading of Cassava Sciences halted at 08:00 AM EST due to "News pending". NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis $1.90 -0.90 (-32.14%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cassava Sciences Stock (NASDAQ:SAVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cassava Sciences alerts:Sign Up Key Stats Today's Range$1.80▼$2.3350-Day Range$1.90▼$2.8452-Week Range$1.80▼$42.20Volume16.20 million shsAverage Volume2.93 million shsMarket Capitalization$91.79 millionP/E RatioN/ADividend YieldN/APrice Target$54.50Consensus RatingModerate Buy Company OverviewCassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More… Remove Ads Cassava Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreSAVA MarketRank™: Cassava Sciences scored higher than 78% of companies evaluated by MarketBeat, and ranked 211th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($3.97) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted33.01% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 9.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.82 Percentage of Shares Shorted33.01% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 9.35%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment-0.02 News SentimentCassava Sciences has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Cassava Sciences this week, compared to 8 articles on an average week.Search InterestOnly 27 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.MarketBeat Follows5 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Stock News HeadlinesCassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpointMarch 26 at 12:07 AM | markets.businessinsider.comCassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’sMarch 26 at 12:07 AM | markets.businessinsider.comA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....March 25, 2025 | Banyan Hill Publishing (Ad)Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains HopefulMarch 26 at 12:07 AM | msn.comCassava to phase out Alzheimer’s program by Q2March 25 at 7:06 PM | msn.comCassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be DiscontinuedMarch 25 at 7:06 PM | marketwatch.comCassava to discontinue development of Alzheimer's disease drugMarch 25 at 7:06 PM | msn.comCassava Sciences' controversial Alzheimer's drug fails in second late-stage studyMarch 25 at 7:06 PM | msn.comSee More Headlines SAVA Stock Analysis - Frequently Asked Questions How have SAVA shares performed this year? Cassava Sciences' stock was trading at $2.36 at the start of the year. Since then, SAVA shares have decreased by 19.5% and is now trading at $1.90. View the best growth stocks for 2025 here. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) announced its earnings results on Monday, March, 3rd. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.11. When did Cassava Sciences' stock split? Shares of Cassava Sciences split before market open on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. Who are Cassava Sciences' major shareholders? Cassava Sciences' top institutional shareholders include Affinity Asset Advisors LLC, Group One Trading LLC, Bank of America Corp DE and Two Sigma Advisers LP (1.26%). Insiders that own company stock include Eric Schoen and James William Kupiec. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings3/03/2025Today3/25/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAVA CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$54.50 High Stock Price Target$107.00 Low Stock Price Target$2.00 Potential Upside/Downside+2,768.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.05% Return on Assets-64.98% Debt Debt-to-Equity RatioN/A Current Ratio3.55 Quick Ratio3.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book0.58Miscellaneous Outstanding Shares48,308,000Free Float43,780,000Market Cap$91.79 million OptionableOptionable Beta-1.24 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SAVA) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.